105 related articles for article (PubMed ID: 32326511)
1. An Explorative Analysis of
Stenvang J; Budinská E; van Cutsem E; Bosman F; Popovici V; Brünner N
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326511
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
Klingbiel D; Saridaki Z; Roth AD; Bosman FT; Delorenzi M; Tejpar S
Ann Oncol; 2015 Jan; 26(1):126-132. PubMed ID: 25361982
[TBL] [Abstract][Full Text] [Related]
3. DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
Nygård SB; Vainer B; Nielsen SL; Bosman F; Tejpar S; Roth A; Delorenzi M; Brünner N; Budinska E
Clin Cancer Res; 2016 Apr; 22(7):1621-31. PubMed ID: 26542057
[TBL] [Abstract][Full Text] [Related]
4. Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.
Buhl IK; Gerster S; Delorenzi M; Jensen T; Jensen PB; Bosman F; Tejpar S; Roth A; Brunner N; Hansen A; Knudsen S
PLoS One; 2016; 11(5):e0155123. PubMed ID: 27171152
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D
J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425
[TBL] [Abstract][Full Text] [Related]
6. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
Stocker G; Hacker UT; Fiteni F; John Mahachie J; Roth AD; Van Cutsem E; Peeters M; Lordick F; Mauer M
Eur J Cancer; 2018 Aug; 99():49-57. PubMed ID: 29906734
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
8. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
[TBL] [Abstract][Full Text] [Related]
9. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
10. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
[TBL] [Abstract][Full Text] [Related]
11. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
Lee KY; Park JW; Lee KY; Cho S; Kwon YH; Kim MJ; Ryoo SB; Jeong SY; Park KJ
Int J Colorectal Dis; 2019 Apr; 34(4):629-639. PubMed ID: 30661101
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
13. Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.
Nielsen DL; Palshof JA; Brünner N; Stenvang J; Viuff BM
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28880238
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
15. A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI.
Paquet ER; Cui J; Davidson D; Pietrosemoli N; Hassan HH; Tsofack SP; Maltais A; Hallett MT; Delorenzi M; Batist G; Aloyz R; Lebel M
J Pathol Clin Res; 2015 Jul; 1(3):160-72. PubMed ID: 27499901
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature.
Gkekas I; Novotny J; Pecen L; Strigård K; Palmqvist R; Gunnarsson U
Anticancer Res; 2017 Dec; 37(12):6563-6574. PubMed ID: 29187431
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
Aranda E; Valladares M; Martinez-Villacampa M; Benavides M; Gomez A; Massutti B; Marcuello E; Constenla M; Cámara JC; Carrato A; Dueñas R; Reboredo M; Navarro M; Díaz-Rubio E
Ann Oncol; 2009 Feb; 20(2):251-7. PubMed ID: 18718892
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
Ychou M; Hohenberger W; Thezenas S; Navarro M; Maurel J; Bokemeyer C; Shacham-Shmueli E; Rivera F; Kwok-Keung Choi C; Santoro A
Ann Oncol; 2009 Dec; 20(12):1964-70. PubMed ID: 19567451
[TBL] [Abstract][Full Text] [Related]
20. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
